Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform

January 21, 2021

Interim data from GINAKIT2 and ANCHOR clinical studies provide evidence of efficacy for Kuur’s chimeric antigen receptor-natural killer T cell (CAR-NKT) platform

First complete responses in patients treated with autologous and allogeneic engineered CAR-NKT cell therapies

Clinical responses, tumor homing and promising safety profile observed in patients treated with CAR-NKT cells in autologous neuroblastoma and allogeneic (off-the-shelf) lymphoma/leukemia studies

HOUSTON – Jan. 21, 2021 – Kuur Therapeutics, the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced clinical updates for both the phase 1 GINAKIT2 study of KUR-501 (autologous GD2 CAR-NKT cells) being tested in patients with relapsed/refractory (R/R) neuroblastoma, and the phase 1 ANCHOR study of KUR-502 (off-the-shelf CD19 CAR-NKT cells) being evaluated in patients with R/R CD19 positive malignancies. Complete responses and evidence of tumor homing have been observed in both trials, and the CAR-NKT cell therapy has been safe and well-tolerated.

“We are very excited by these results, which help validate the biology and clinical activity of CAR-NKT cells. Although these are phase 1 studies and continue to recruit patients, we are pleased we have been able to demonstrate tumor homing, an important property of CAR-NKT cells, along with an excellent safety profile,” said Kurt Gunter MD, Kuur Chief Medical Officer. “We are grateful to the patients and families for their participation in these studies and to the scientists and physicians at Baylor College of Medicine for their scientific leadership.”

“We are encouraged by the evidence of clinical activity with an allogeneic approach, especially at such a low dose,” said Dr. Carlos Ramos, Principal Investigator of the ANCHOR study, Professor of Medicine at the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine, and member of the Dan L Duncan Comprehensive Cancer Center. “We look forward to advancing the program and treating additional patients.”

In the GINAKIT2 study, out of ten evaluable patients and with escalation to a dose level (DL) of 1×108 cells/m2, one complete response (CR) and one partial response (PR) have been observed to date, with stable disease (SD) in three additional patients. The patient with the CR is notable in that a PR was observed after the initial 1×108 cells/m2 dose, and a subsequent single dose at the same level deepened the response to a CR. Tumor biopsies show CAR-NKT cells homing to the neuroblastoma tumor site at all dose levels. KUR-501 has so far demonstrated a promising safety profile, with only one case of grade two cytokine release syndrome (CRS) and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS).

In the ANCHOR study, of the two evaluable lymphoma patients treated to date at the starting DL of 1×107 cells/m2, one patient has experienced a CR and the other a PR. The patient with a CR was initially observed to be in PR four weeks after infusion but subsequently converted to a CR without additional therapy. Biopsy of the patient’s lymph node prior to conversion to CR status revealed viable, allogeneic CD19 CAR-NKT cells. The patient with a PR had previously failed autologous CAR-T cell therapy. KUR-502 has so far demonstrated a promising safety profile with no CRS, no ICANS, and no evidence of graft versus host disease (GvHD).

“We are very pleased to be able to report the first complete response in a patient treated with an allogeneic engineered CAR-NKT cell therapy,” said Kevin S. Boyle, Sr., Chief Executive Officer of Kuur. “The clinical activity and safety data from both clinical trials are encouraging for the potential of our innovative CAR-NKT cell platform to create effective therapies for cancer patients.”

The trials are being conducted at Baylor College of Medicine (Kuur’s CAR-NKT cell platform partner), Houston Methodist Hospital and Texas Children’s Hospital.

About KUR-501
KUR-501 is an autologous product in which natural killer T (NKT) cells are engineered with a chimeric antigen receptor (CAR) targeting GD2, which is expressed on almost all neuroblastoma tumors. KUR-501 is also designed to address key limitations of current CAR immune cell therapies by secreting the cytokine IL-15, which has been shown in nonclinical studies to increase the persistence of CAR-NKT cells and improve their efficacy within the immunosuppressive tumor microenvironment. KUR-501 is being tested in a phase 1 GINAKIT2 clinical study (NCT03294954) in patients with R/R high-risk neuroblastoma. The KUR-501 development program is also designed to provide autologous proof-of-concept for CAR-NKT cells in solid tumors using a validated target and has extensive potential applications in the treatment of hematological and solid tumors.

About KUR-502
KUR-502 is built on Kuur’s next-generation CAR-NKT platform with novel engineering capabilities that harness and enhance the unique tumor-homing properties of NKT cells. The NKT cells used in Kuur’s CAR-NKT platform have an invariant T cell receptor that does not distinguish between self- and non-self tissues, making the cells unlikely to induce GvHD when given to another person. Preclinical data generated by Baylor College of Medicine indicate that while human CAR-T cells cause severe GvHD, CAR-NKT cells from the same donor do not.

The ANCHOR (NCT03774654) study is a phase 1, first-in-human, dose escalation evaluation of KUR-502 in adults with R/R CD19 positive malignancies including B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The single-arm study will evaluate three dose levels with patients receiving lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by infusion with KUR-502.

Patients with R/R CD19 positive malignancies have limited effective treatment options. While CD19-directed autologous CAR-T cells are now available for these patients, they are limited by delays to get treatment, a requirement for patient leukapheresis, and issues with inferior quality leukapheresis starting material due to prior treatment. Off-the-shelf KUR-502 is designed to overcome these limitations.

The ANCHOR study is being sponsored and conducted by Kuur’s collaborator, Baylor College of Medicine and is currently recruiting participants.

About Kuur Therapeutics
Kuur Therapeutics is a clinical-stage biopharmaceutical company focused on the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies. The company’s revolutionary platform engineers CARs expressed by invariant NKT cells, which combine features of T and NK cells, and is being developed in partnership with Baylor College of Medicine and Texas Children’s Hospital. Allogeneic cell therapy has the potential to be much faster and less expensive than patient-specific autologous products, and NKT cells offer several advantages over other cell types for allogeneic immunotherapy applications. NKT cells have the cytotoxic and anti-tumor properties of conventional T cells, but with other biological attributes that are expected to improve their ability to attack hematological and solid tumors. These include innate tissue and solid tumor homing properties, as well as endogenous anti-tumor activity based on the ability to eliminate immune suppressive cells and activate host immune cells within the tumor microenvironment.

About Baylor College of Medicine
Baylor College of Medicine in Houston is recognized as a premier health sciences university and is known for excellence in education, research, and patient care. It is the only private medical school in the greater southwest and is ranked 22nd among medical schools for research and 4th for primary care by U.S. News & World Report. Baylor is listed 20th among all U.S. medical schools for National Institutes of Health funding and No. 1 in Texas. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Luke’s Medical Center, part of CHI St. Luke’s Health. Currently, Baylor has more than 3,000 trainees in medical, graduate, nurse anaesthesia, physician assistant, orthotics and genetic counselling, as well as residents and postdoctoral fellows. Follow Baylor College of Medicine on Facebook and Twitter

Investor Contact
Stephanie Ascher
Stern Investor Relations, Inc.

Other News